Recent clinical studies have shown that in renal cell cancer (RCC) patients, A2aR and PD-L1 expression in the primary tumors may foresee the consequences of therapy with anti-VEGF agents and ICIs (51), and the A2aR antagonist ciforadenant showed monotherapy activity in patients who were resistant to or intractable to previous anti-PD-L1 therapy. This evidence concerns the gene CD274 and renal cell adenocarcinoma.